Effectiveness Transfer Energy Capacitive and Resistive Therapy in Patients With Carpal Tunnel Syndrome

Not Applicable

Completed

• Conditions: Energy Transfer Capacitative and Resistive Therapy; Carpal Tunnel Syndrome
• Interventions: Device: US therapy; Device: TECAR

• Registration Number: NCT06451094
• Lead Sponsor: Ankara City Hospital Bilkent

Brief Summary

Objective: The aim of this study was to evaluate the effect of Transfer Energy Capacitive and Resistive (TECAR) therapy on pain, symptom severity and function in patients diagnosed with carpal tunnel syndrome (CTS) based on clinical and electromyography (EMG) findings and to compare it with ultrasound therapy (US).

Methods: A total of 42 patients aged between 18 and 65 years, were randomly divided into two groups; group 1, US therapy 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions, group 2 TECAR therapy 5 min capacitive (CAP) and 10 min resistive (RES), 3 days a week for 2 weeks, for a total of 6 sessions. Both groups received paraffin therapy and wrist orthosis. All Patients were evaluated using the Visual Analog Scale (VAS) for pain and paresthesia levels, the Boston Carpal Tunnel Questionnaire (BCTQ) for symptom severity and functional levels. Additionally, median nerve CSA was measured by ultrasound, at the baseline, post-treatment, first and third months.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-15
• Primary Completion: 2023-11-15
• Study Completion: 2024-02-15
• Status Verified: 2024-06
• Study First Submitted: 2024-06-03
• Study First Submitted QC: 2024-06-07
• Study First Posted: 2024-06-10
• Last Update Submitted: 2024-06-10
• Last Update Posted: 2024-06-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

• 18 years of age and over
• had pain and numbness in their hands for more than 3 months were evaluated
• Patients diagnosed with mild and moderate CTS by EMG

Exclusion Criteria

• metabolic, rheumatic, or neurological diseases that could affect the median nerve cross-sectional area (CSA)
• patients who had previously undergone surgery on the wrist,
• oncology patients,
• pregnancy,
• pacemakers.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
US therapy, paraffin therapy	US therapy	Group 1, US therapy to the palmar region of the wrist, 5 minutes intermittently for 2 weeks, 5 times a week, for a total of 10 sessions and Paraffin therapy to the wrist area by dipping the hand 3 times into a paraffin bath and removing it, covering the entire wrist with paraffin, and waiting for 15 min (2 weeks, 5 times a week, for a total of 10 sessions).
TECAR therapy, paraffin therapy	TECAR	Group 2, TECAR therapy to the palmar region of the wrist, 5 min capacitive (CAP) and 10 min resistive (RES), 3 days a week for 2 weeks, for a total of 6 sessions and Paraffin therapy to the wrist area by dipping the hand 3 times into a paraffin bath and removing it, covering the entire wrist with paraffin, and waiting for 15 min (2 weeks, 5 times a week, for a total of 10 sessions).

Primary Outcome Measures

Name	Time	Method
Visual Analog Scale (VAS)	baseline (0 th day), after-treatment (15 th day), 1th month, 3rd month	0 min , 10 is maximum pain score
Boston Carpal Tunnel Questionnaire (BCTQ)	baseline (0 th day), after-treatment (15 th day), 1th month, 3rd month	symptom severity on functional tasks (Symptom Severity Scale), involving 11 items, and the other one on function status properly (Functional Status Scale), involving 8 items. Both subscales of BCTQ are scored between 1 and 5, and higher scores illustrate a greater degree of disability.

Secondary Outcome Measures

Name	Time	Method
Median nerve cross-sectional area (CSA) measurement	baseline (0 th day), after-treatment (15 th day), 1th month, 3rd month	Median nerve CSA was measured by ultrasound on axial view at the scaphoid-pisiform level which is a reliable measurement for CTS. Three measurements were taken for analysis and the average value was recorded

Trial Locations

Locations (1)

Özge TEZEN; 🇹🇷 Ankara, Turkey